Contrasting Innate Pharma (OTCMKTS:IPHYF) and MeiraGTx (NASDAQ:MGTX)

Innate Pharma (OTCMKTS:IPHYF) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.

Profitability

This table compares Innate Pharma and MeiraGTx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
MeiraGTx	-633.05%	-146.38%	-53.05%

Earnings & Valuation

This table compares Innate Pharma and MeiraGTx”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$66.71 million	3.49	-$8.19 million	N/A	N/A
MeiraGTx	$13.93 million	33.16	-$84.03 million	($1.21)	-4.88

Innate Pharma has higher revenue and earnings than MeiraGTx.

Volatility and Risk

Innate Pharma has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.

Institutional & Insider Ownership

67.5% of MeiraGTx shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 8.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Innate Pharma and MeiraGTx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	0	0	0	0	0.00
MeiraGTx	0	0	2	0	3.00

MeiraGTx has a consensus target price of $23.50, suggesting a potential upside of 297.63%. Given MeiraGTx’s stronger consensus rating and higher probable upside, analysts plainly believe MeiraGTx is more favorable than Innate Pharma.

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.